Genomic, phenotypic, and functional analyses of T cells in patients with psoriasis undergoing systemic cyclosporin A treatment - PubMed (original) (raw)
Genomic, phenotypic, and functional analyses of T cells in patients with psoriasis undergoing systemic cyclosporin A treatment
A Takashima et al. J Invest Dermatol. 1991 Mar.
Free article
Abstract
Recent studies have demonstrated that cyclosporin A (CyA) exerts a beneficial effect on psoriasis. It remains unclear, however, whether T-cell immune responses are definitely impaired in psoriasis and whether the anti-psoriatic effect of CyA is mediated by interference with T-cell activation. To study these questions, 20 patients with severe psoriasis were treated with oral CyA (5 mg/kg/d) for 12 weeks and examined for several phenotypic and functional properties of peripheral blood T cells before and after therapy. The analyses included CD3, CD4, and CD8 phenotypes, IL-2 production and IL-2 receptor expression following Con A stimulation, proliferative responses to PHA, and in vivo responsiveness to a foreign antigen, PPD. When the values of patients before therapy and healthy individuals were compared, no statistically significant differences were detected in any of these analyses. Furthermore, none of these T-cell properties were changed after 12 weeks of treatment. To assess possible minor mutations in T-cell-related genes in psoriasis, the T-cell receptor beta-chain locus was analyzed by Southern hybridization. With a cDNA probe for C beta 1, a polymorphic fragment of congruent to 9 kb was detected in Eco RI digests in one of 20 patients and in four of 10 healthy individuals examined. No polymorphism was detected in Bam HI digests in any individual. These results fail to support the hypothesis that a general or "systemic" alteration in T-cell immunity plays a central role in the pathogenesis of psoriasis and in the action of CyA against this skin disorder.
Similar articles
- Influence of systemic cyclosporin A on interleukin-2 and epidermal growth factor receptor expression in psoriatic skin lesions.
Horroccks A, Ormerod AD, Duncan JI, Thomson AW. Horroccks A, et al. Clin Exp Immunol. 1989 Nov;78(2):166-71. Clin Exp Immunol. 1989. PMID: 12412743 Free PMC article. - Intralesional cyclosporin in psoriasis: effects on T lymphocyte and dendritic cell subpopulations.
Baker BS, Powles AV, Savage CR, McFadden JP, Valdimarsson H, Fry L. Baker BS, et al. Br J Dermatol. 1989 Feb;120(2):207-13. doi: 10.1111/j.1365-2133.1989.tb07784.x. Br J Dermatol. 1989. PMID: 2784322 Clinical Trial. - The role of the T cell in psoriasis and the action of cyclosporin in this disease.
Fry L. Fry L. Acta Derm Venereol Suppl (Stockh). 1989;146:133-4; discussion 134-5. Acta Derm Venereol Suppl (Stockh). 1989. PMID: 2609854 No abstract available. - Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia.
Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD. Bata-Csorgo Z, et al. J Invest Dermatol. 1995 Jul;105(1 Suppl):89S-94S. doi: 10.1111/1523-1747.ep12316121. J Invest Dermatol. 1995. PMID: 7616005 Review. - Efficacy of cyclosporin A in psoriasis: a summary of the United States' experience.
Fradin MS, Ellis CN, Voorhees JJ. Fradin MS, et al. Br J Dermatol. 1990 Jun;122 Suppl 36:21-5. doi: 10.1111/j.1365-2133.1990.tb02878.x. Br J Dermatol. 1990. PMID: 2196080 Review.
Cited by
- Immune Parameters of Korean Patients with Psoriasis Treated with Low-Dose Cyclosporine.
Choi JH, Shin EJ, Shin MK, Kim NI. Choi JH, et al. Ann Dermatol. 2017 Feb;29(1):111-113. doi: 10.5021/ad.2017.29.1.111. Epub 2017 Feb 3. Ann Dermatol. 2017. PMID: 28223761 Free PMC article. No abstract available. - A global gene expression analysis of the peripheral blood mononuclear cells reveals the gene expression signature in psoriasis.
Lee SK, Jeon EK, Kim YJ, Seo SH, Kim CD, Lim JS, Lee JH. Lee SK, et al. Ann Dermatol. 2009 Aug;21(3):237-42. doi: 10.5021/ad.2009.21.3.237. Epub 2009 Aug 31. Ann Dermatol. 2009. PMID: 20523796 Free PMC article. - IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach.
Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, Döcke WD. Asadullah K, et al. J Clin Invest. 1998 Feb 15;101(4):783-94. doi: 10.1172/JCI1476. J Clin Invest. 1998. PMID: 9466973 Free PMC article. Clinical Trial. - Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines.
Nestle FO, Turka LA, Nickoloff BJ. Nestle FO, et al. J Clin Invest. 1994 Jul;94(1):202-9. doi: 10.1172/JCI117308. J Clin Invest. 1994. PMID: 8040262 Free PMC article. - Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model.
Nickoloff BJ, Kunkel SL, Burdick M, Strieter RM. Nickoloff BJ, et al. Am J Pathol. 1995 Mar;146(3):580-8. Am J Pathol. 1995. PMID: 7887440 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous